5a674268-79a8-4a30-a6db-a4fd0b83e208
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.500
- COAGULATION+0.500
- IL6_JAK_STAT3_SIGNALING+0.500
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.500
- COMPLEMENT+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- INFLAMMATORY_RESPONSE+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- IL2_STAT5_SIGNALING+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.400
- MITOTIC_SPINDLE-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- ADIPOGENESIS-0.200
- DNA_REPAIR-0.200
- FATTY_ACID_METABOLISM-0.200
- MYC_TARGETS_V1-0.200
- UV_RESPONSE_DN-0.200
- WNT_BETA_CATENIN_SIGNALING-0.200
- CHOLESTEROL_HOMEOSTASIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR597977 | GTEX | — | 0.906 |
| 2 | MDT-AP-0363 | Med | Medulloblastoma | 0.896 |
| 3 | SRR601755 | GTEX | — | 0.890 |
| 4 | SRR1382532 | GTEX | — | 0.890 |
| 5 | TCGA-77-8131-01A-11R-2247-07 | — | cohortSQ1 | 0.889 |
| 6 | SRR1469495 | GTEX | — | 0.889 |
| 7 | MNG663 | — | — | 0.883 |
| 8 | BS_HJRTC9JQ | high-grade glioma | — | 0.877 |
| 9 | MDT-AP-2621 | Med | Medulloblastoma | 0.871 |
| 10 | s0122149 | — | — | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| COAGULATION | 0.500 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |